OptiNose/OPTN

$0.97

8.42%
-
1D1W1MYTD1YMAX

About OptiNose

OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

Ticker

OPTN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ramy Mahmoud

Employees

132

Headquarters

Yardley, United States

OptiNose Metrics

BasicAdvanced
$100.73M
Market cap
-
P/E ratio
-$0.32
EPS
-0.09
Beta
-
Dividend rate
$100.73M
-0.08784
$2.10
$0.89
593.82K
0.597
0.551
-1.79%
-28.17%
1.419
-6.93%
64.09%
13.06%

What the Analysts think about OptiNose

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
286.6% upside
High $5.00
Low $3.00
$0.97
Current price
$3.75
Average price target

OptiNose Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-50% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$19.8M
0%
Net income
$-9.9M
7.61%
Profit margin
-50%
7.62%

OptiNose Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 4.59%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.17
$0.02
-$0.08
-$0.09
-
Expected
-$0.14
-$0.11
-$0.09
-$0.09
-$0.11
Surprise
22.01%
-118.43%
-15.19%
-4.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for OptiNose stock?

OptiNose (OPTN) has a market cap of $100.73M as of April 22, 2024.

What is the P/E ratio for OptiNose stock?

The price to earnings (P/E) ratio for OptiNose (OPTN) stock is 0 as of April 22, 2024.

Does OptiNose stock pay dividends?

No, OptiNose (OPTN) stock does not pay dividends to its shareholders as of April 22, 2024.

When is the next OptiNose dividend payment date?

OptiNose (OPTN) stock does not pay dividends to its shareholders.

What is the beta indicator for OptiNose?

OptiNose (OPTN) has a beta rating of -0.09. This means that it has an inverse relation to market volatility.

What is the OptiNose stock price target?

The target price for OptiNose (OPTN) stock is $3.75, which is 286.6% above the current price of $0.97. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell OptiNose stock

Buy or sell OptiNose stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing